Timothy Rolph Sells 12,500 Shares of Akero Therapeutics (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 12,500 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $46.08, for a total value of $576,000.00. Following the completion of the transaction, the insider owned 166,571 shares of the company’s stock, valued at approximately $7,675,591.68. This trade represents a 6.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Timothy Rolph also recently made the following trade(s):

• On Thursday, September 11th, Timothy Rolph sold 553 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.02, for a total value of $23,790.06.
• On Monday, September 8th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.17, for a total value of $552,125.00.
• On Tuesday, August 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $49.30, for a total value of $616,250.00.

Akero Therapeutics Price Performance

Shares of Akero Therapeutics stock opened at $53.88 on Friday. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of -26.94 and a beta of -0.29. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.66 and a current ratio of 12.66. The stock has a 50 day moving average price of $47.15 and a 200-day moving average price of $46.78. Akero Therapeutics, Inc. has a one year low of $21.34 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, August 8th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.11. During the same period in the previous year, the firm posted ($0.81) earnings per share. Equities analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on AKRO. Cowen began coverage on Akero Therapeutics in a report on Monday, August 4th. They set a “buy” rating for the company. Jefferies Financial Group cut Akero Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the company from $75.00 to $56.00 in a report on Thursday. TD Cowen began coverage on Akero Therapeutics in a report on Monday, August 4th. They set a “buy” rating and a $76.00 price objective for the company. HC Wainwright restated a “neutral” rating and set a $54.00 price objective (down previously from $72.00) on shares of Akero Therapeutics in a report on Friday. Finally, Canaccord Genuity Group cut Akero Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the company from $73.00 to $54.00 in a report on Thursday. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $73.38.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AKRO. GAMMA Investing LLC raised its position in Akero Therapeutics by 8,057.1% during the 1st quarter. GAMMA Investing LLC now owns 10,849 shares of the company’s stock valued at $439,000 after purchasing an additional 10,716 shares in the last quarter. Rhumbline Advisers raised its position in Akero Therapeutics by 4.7% during the 1st quarter. Rhumbline Advisers now owns 110,687 shares of the company’s stock valued at $4,481,000 after purchasing an additional 5,001 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in Akero Therapeutics during the 1st quarter valued at $297,000. Mirae Asset Global Investments Co. Ltd. raised its position in Akero Therapeutics by 14.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock valued at $114,000 after purchasing an additional 338 shares in the last quarter. Finally, KBC Group NV bought a new stake in Akero Therapeutics during the 1st quarter valued at $120,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.